Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-Cell responses to the tumor-specific antigen NY-ESO-1

被引:55
|
作者
Le Gal, FA
Ayyoub, M
Dutoit, V
Widmer, V
Jäger, E
Cerottini, JC
Dietrich, PY
Valmori, D
机构
[1] Columbia Univ, Coll Phys & Surg, Dept Med, Ludwig Inst,Clin Trial Ctr,Div Med Oncol, New York, NY 10032 USA
[2] Univ Hosp Geneva, Div Oncol, Lab Tumor Immunol, Geneva, Switzerland
[3] Krankenhaus Nordw, Med Klin 2, Frankfurt, Germany
[4] Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland
关键词
T-cell receptor; repertoire; tumor immunity; vaccination;
D O I
10.1097/01.cji.0000161398.34701.26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Spontaneous immune responses to the cancer testis antigen NY-ESO-1 are frequently found in cancer patients bearing antigen-expressing tumors. In HLA-A2-expressing patients, naturally elicited NY-ESO-1-specific, tumor-reactive cytotoxic T lymphocytes (CTLs) are mostly directed against an immunodominant epilope corresponding to peptide NY-ESO-1 157-165. NY-ESO-1-specific CTLs can also be induced by synthetic peptide vaccines. but they are heterogeneous in terms of functional avidity and tumor reactivity, The authors investigated the structural bases of this phenomenon by analyzing the TCR features of natural and vaccine-induced NY-ESO-1-specific CTLs. The results indicate that CTLs from the two groups exhibit highly structurally conserved but distinct TCR features, suggesting that the synthetic peptides used for vaccination may rail to faithfully mimic the naturally processed antigen. Together, the results of this study underline the strength of TCR molecular monitoring and will be instrumental for the development and monitoring of vaccines aimed at eliciting CTLs with high tumor reactivity.
引用
收藏
页码:252 / 257
页数:6
相关论文
共 50 条
  • [11] Kinetics and Phenotype of Vaccine-Induced CD8+ T-Cell Responses to Toxoplasma gondii
    Jordan, Kimberly A.
    Wilson, Emma H.
    Tait, Elia D.
    Fox, Barbara A.
    Roos, David S.
    Bzik, David J.
    Dzierszinski, Florence
    Hunter, Christopher A.
    INFECTION AND IMMUNITY, 2009, 77 (09) : 3894 - 3901
  • [12] CD8+ T-cell response to NY-ESO-1:: Relative antigenicity and in vitro immunogenicity of natural and analogue sequences
    Romero, P
    Dutoit, V
    Rubio-Godoy, V
    Liénard, D
    Speiser, D
    Guillaume, P
    Servis, K
    Rimoldi, D
    Cerottini, JC
    Valmori, D
    CLINICAL CANCER RESEARCH, 2001, 7 (03) : 766S - 772S
  • [13] Naturally occurring human lymphocyte antigen-A2 restricted CD8+T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
    Valmori, D
    Dutoit, V
    Liénard, D
    Rimoldi, D
    Pittet, MJ
    Champagne, P
    Ellefsen, K
    Sahin, U
    Speiser, D
    Lejeune, F
    Cerottini, JC
    Romero, P
    CANCER RESEARCH, 2000, 60 (16) : 4499 - 4506
  • [14] Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Yuan, Jianda
    Adamow, Matthew
    Ginsberg, Brian A.
    Rasalan, Teresa S.
    Ritter, Erika
    Gallardo, Humilidad F.
    Xu, Yinyan
    Pogoriler, Evelina
    Terzulli, Stephanie L.
    Kuk, Deborah
    Panageas, Katherine S.
    Ritter, Gerd
    Sznol, Mario
    Halaban, Ruth
    Jungbluth, Achim A.
    Allison, James P.
    Old, Lloyd J.
    Wolchok, Jedd D.
    Gnjatic, Sacha
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (40) : 16723 - 16728
  • [15] Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses
    Simona Stäger
    James Alexander
    Alun C Kirby
    Marina Botto
    Nico Van Rooijen
    Deborah F Smith
    Frank Brombacher
    Paul M Kaye
    Nature Medicine, 2003, 9 : 1287 - 1292
  • [16] Tumor Antigen NY-ESO-1-Derived CD8+ T-cell Epitopes are Presented Differently by DCs and Melanoma Cells
    Chen, Weisan
    Ebert, Lisa
    Robson, Neil
    Zhao, Rona
    Mifsud, Nicole A.
    McAlpine, Iristan
    Xiao, Kun
    Jackson, Heather
    Dimopoulos, Nektaria
    Guillaume, Philippe
    Russell, Sarah E.
    Scotet, Emmanuel
    Luescher, Immanuel F.
    Davis, Ian D.
    Maraskovsky, Eugene
    Cebon, Jonathan S.
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (09) : 956 - 956
  • [17] Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses
    Stäger, S
    Alexander, J
    Kirby, AC
    Botto, M
    Van Rooijen, N
    Smith, DF
    Brombacher, F
    Kaye, PM
    NATURE MEDICINE, 2003, 9 (10) : 1287 - 1292
  • [18] Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
    Song, Mi-Young
    Park, Sang-Hoon
    Nam, Hyo Jung
    Choi, Dong-Hoon
    Sung, Young-Chul
    JOURNAL OF IMMUNOTHERAPY, 2011, 34 (03) : 297 - 306
  • [19] Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity
    Cohen, AD
    Diab, A
    Perales, MA
    Wolchok, JD
    Rizzuto, G
    Merghoub, T
    Huggins, D
    Liu, CL
    Turk, MJ
    Restifo, NP
    Sakaguchi, S
    Houghton, AN
    CANCER RESEARCH, 2006, 66 (09) : 4904 - 4912
  • [20] Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses
    Cousin, Nikola
    Cap, Stefan
    Dihr, Manuel
    Tacconi, Carlotta
    Detmar, Michael
    Dieterich, Lothar C.
    CANCER RESEARCH, 2021, 81 (15) : 4133 - 4144